Huang Dennis Karl 4
4 · Ultragenyx Pharmaceutical Inc. · Filed Mar 3, 2023
Insider Transaction Report
Form 4
Huang Dennis Karl
See Remarks
Transactions
- Award
Common Stock
2023-03-01+2,663→ 53,703 total - Award
Common Stock
2023-03-01+22,000→ 75,703 total - Sale
Common Stock
2023-03-01$45.65/sh−389$17,758→ 75,314 total - Disposition to Issuer
Common Stock
2023-03-01$45.65/sh−10,599$483,844→ 64,715 total - Award
Stock Option (Right to Buy)
2023-03-01+39,400→ 39,400 totalExercise: $45.65Exp: 2033-03-01→ Common Stock (39,400 underlying)
Footnotes (6)
- [F1]Represents shares of common stock which previously granted performance stock units were converted on March 1, 2023 upon certification of the performance metric.
- [F2]Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.
- [F3]Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
- [F4]Shares were acquired upon the partial vesting of a previously reported RSU and were sold to permit the cash value of the awards to be credited to the deferred compensation plan account of the Reporting Person.
- [F5]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F6]On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.